Fig. 1

The correlation analysis between SKA3 expression and clinical parameters and the effect of SKA3 expression on the proliferation ability of PCA cells. A The differential expressions of SKA3 in pan-cancer level using non-paired samples; B the differential expressions of SKA3 in pan-cancer level using paired samples; C the differential expressions of SKA3 in PCA using non-paired samples; D the differential expressions of SKA3 in PCA using paired samples; E Relative expression of SKA3 among prostate normal and tumor cell lines; F the ROC curve of SKA3 distinguishing tumor from normal; G the ROC curve of SKA3 distinguishing T2–3 from T4; H Kaplan–Meier curve showing progress free survival of high and low expression of SKA3; I Kaplan–Meier curve showing progress free survival of high and low expression of SKA3 in patients with T3 stage; J Kaplan–Meier curve showing progress free survival of high and low expression of SKA3 in patients with N0 stage; K Kaplan-Meier curve showing progress free survival of high and low expression of SKA3 in patients with M0 stage; L Kaplan–Meier curve showing progress free survival of high and low expression of SKA3 in patients with PSA < 4 ng/ml; M Kaplan–Meier curve showing progress free survival of high and low expression of SKA3 in patients with positively residual tumor; N Kaplan–Meier curve showing progress free survival of high and low expression of SKA3 in white patients; O RT–qPCR results of SKA3 siRNAs; P effect of SKA3 siRNAs on LNCap using CCK8 assay; Q effect of SKA3 siRNAs on C4-2 using CCK8 assay; R effect of SKA3 siRNAs on C4-2B using CCK8 assay; S effect of SKA3 siRNAs on PC3 using CCK8 assay; T effect of SKA3 siRNAs on DU145 using CCK8 assay. ROC = receiver operating characteristic curve. R = residual tumor. RT–qPCR = Real-time quantitative polymerase chain reaction